SCHEMBL18354536

SCHEMBL18354536

CCN(C(=O)c1ccc(C(F)(F)F)cc1)c1cccc(C(=O)Nc2c(Br)cc(C(F)(C(F)(F)F)C(F)(F)F)cc2OC(F)F)c1OC

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTTP P55157 4/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
PTPN1 P18031 1/20 0.33
RXFP1 Q9HBX9 2/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SCN8A Q9UQD0 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
PPARA Q07869 1/20 0.32
MCHR1 Q99705 1/20 0.32
CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18354649 0.94 LMNA (0.35) SMN1; SMN2HDAC8RXFP1NPC1ALDH1A1
SCHEMBL18354651 0.94 MAPT (0.34) SMN1; SMN2HDAC8NPC1ALDH1A1LMNA
SCHEMBL18354705 0.94 MAPT (0.34) SMN1; SMN2HDAC8RXFP1NPC1ALDH1A1
SCHEMBL18354632 0.93 MLYCD (0.36) SMN1; SMN2HDAC8RXFP1NPC1ALDH1A1
SCHEMBL18354191 0.92 HDAC8 (0.34) SMN1; SMN2HDAC8NPC1ALDH1A1LMNA
SCHEMBL18354645 0.92 HDAC8 (0.34) MTTPSMN1; SMN2HDAC8RXFP1LMNA
SCHEMBL18354685 0.91 MLYCD (0.38) SMN1; SMN2HDAC8RXFP1NPC1ALDH1A1
SCHEMBL18354718 0.91 TAS1R3 (0.39) MTTPSMN1; SMN2NPC1MAPTRAB9A
SCHEMBL18354408 0.91 MAPT (0.35) SMN1; SMN2RXFP1NPC1ALDH1A1LMNA
SCHEMBL18355489 0.91 MLYCD (0.35) SMN1; SMN2NPC1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210051955-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2021-02-25 US disclosed
US-20200253205-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2020-08-13 US disclosed
US-20190075792-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2019-03-14 US disclosed
US-20180077930-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-03-22 US disclosed
US-20180077930-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-03-22 US disclosed
US-9839216-B2 Insecticidal compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-12-12 US disclosed
US-9839216-B2 Insecticidal compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-12-12 US disclosed
US-20170000120-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2017-01-05 US disclosed
US-20170000120-A1 INSECTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2017-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200253205-A1 INSECTICIDAL COMPOUNDS ACHE, CYP4X1, ITPR3 MTTP 1826/4885SMN1; SMN2 1665/4885HDAC8 1076/4885
US-20180077930-A1 INSECTICIDAL COMPOUNDS ACHE, CYP4X1, ITPR3 MTTP 1826/4885SMN1; SMN2 1665/4885HDAC8 1076/4885
US-20210051955-A1 INSECTICIDAL COMPOUNDS ACHE, CYP4X1, ITPR3 MTTP 1826/4885SMN1; SMN2 1665/4885HDAC8 1076/4885
US-20190075792-A1 INSECTICIDAL COMPOUNDS ACHE, CYP4X1, ITPR3 MTTP 1826/4885SMN1; SMN2 1665/4885HDAC8 1076/4885
US-20170000120-A1 INSECTICIDAL COMPOUNDS ACHE, HDAC6, TUBA3C MTTP 1357/4885SMN1; SMN2 1416/4885HDAC8 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.